Equities Analysts Offer Predictions for CANF FY2026 Earnings

Can-Fite BioPharma Ltd. (NYSE:CANF) – Research analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of Can-Fite BioPharma in a research note issued on Thursday, July 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.68) for the year, up from their prior estimate of ($1.04). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for Can-Fite BioPharma’s FY2027 earnings at ($0.27) EPS, FY2028 earnings at $0.12 EPS and FY2029 earnings at $0.39 EPS.

Several other research firms also recently issued reports on CANF. Zacks Research raised shares of Can-Fite BioPharma to a “hold” rating in a report on Wednesday, May 13th. D. Boral Capital upgraded shares of Can-Fite BioPharma from a “hold” rating to a “buy” rating in a report on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Can-Fite BioPharma has an average rating of “Moderate Buy” and a consensus price target of $44.00.

Can-Fite BioPharma Stock Up 1.2%

Shares of CANF stock opened at $3.85 on Tuesday. Can-Fite BioPharma has a 12 month low of $2.56 and a 12 month high of $21.00. The company has a market cap of $2.52 million, a PE ratio of -2.11 and a beta of 1.11. The business’s 50 day moving average is $3.24 and its two-hundred day moving average is $3.70.

Institutional Investors Weigh In On Can-Fite BioPharma

Hedge funds have recently modified their holdings of the business. Rhumbline Advisers grew its stake in shares of Can-Fite BioPharma by 42.4% in the first quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock worth $57,000 after acquiring an additional 11,388 shares during the last quarter. Jane Street Group LLC acquired a new stake in Can-Fite BioPharma in the 4th quarter worth $41,000. Finally, Sabby Management LLC increased its holdings in shares of Can-Fite BioPharma by 80.3% during the 3rd quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock worth $871,000 after purchasing an additional 626,306 shares during the period. 21.00% of the stock is owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).